Keytruda demonstrates superior overall survival to chemotherapy in NSCLC study
26 October 2015 | By Victoria White
The Phase 2/3 KEYNOTE-010 trial compared two doses of Keytruda to docetaxel...
List view / Grid view
News
CHMP adopts positive opinion of Edurant in adolescents with HIV-1
26 October 2015 | By Victoria White
If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time...
Aprea announces preliminary study data for APR-246 in ovarian cancer
26 October 2015 | By Victoria White
APR-246 combined with standard of care chemotherapy shows activity in the treatment of recurrent ovarian cancer...
FDA approves Yondelis for liposarcoma and leiomyosarcoma
26 October 2015 | By Victoria White
The approval was based on recently published clinical efficacy and safety data from a Phase 3 study which evaluated Yondelis versus the chemotherapy agent dacarbazine...
Bristol-Myers Squibb’s BMS-955176 completes proof-of-concept study
23 October 2015 | By Victoria White
BMS-955176 is a second-generation maturation inhibitor designed to inhibit one of the last steps of the HIV-1 viral lifecycle...
CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
CHMP adopts positive opinion for melanoma treatment Imlygic
23 October 2015 | By Victoria White
If approved by the European Commission, Imlygic would be the first in a class of novel agents known as oncolytic immunotherapies...
New ProtectionPlus module for 21 CFR Part 11 compliance with HORIBA Raman systems
23 October 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in Raman spectroscopy systems for over 50 years, announces the release of their new ProtectionPlus module for the acclaimed LabSpec 6 Spectroscopy Suite...
Ipsen announces additional Phase III study results for Dysport
23 October 2015 | By Victoria White
The Phase III study evaluated the investigational use of Dysport for the treatment of spastic equinus foot, a condition associated with cerebral palsy in children aged 2-17...
EC maintains orphan drug designation for Basilea’s isavuconazole
23 October 2015 | By Victoria White
Isavuconazole will benefit from ten years of market exclusivity associated with orphan medicinal product status in the European Union...
MHRA seizes huge haul of unlicensed medicines
23 October 2015 | By Victoria White
MHRA Enforcement officers seized nearly £1 million worth of unlicensed erectile dysfunction medicines from an address in Slough...
Global Clostridium difficile infections market to hit $1.5b by 2024
23 October 2015 | By Victoria White
GlobalData says this increase will be driven by the modest uptake of patent-protected, Clostridium difficile infection-specific antibiotics and the arrival of novel non-antibiotic approaches...
Gilead announces Phase 3 results for investigational HIV treatment Genvoya
22 October 2015 | By Victoria White
Genvoya was found to be statistically non-inferior to Stribild based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL...
MacroGenics and Merck to study margetuximab and pembrolizumb in gastric cancer
22 October 2015 | By Victoria White
Trial startup activities are underway and MacroGenics expects to begin enrolling patients by the first quarter of 2016...
New UV-Vis Spectrophotometer simplifies sample quality decisions
Life scientists who work with DNA, RNA and proteins can make educated decisions about sample suitability in experiments using a standalone, microvolume spectrophotometer for accurate quantitation and purity measurements to ensure downstream application success.
